EUVIMEDEUVIMED entdecken
Crossref

Identification and Optimization of Novel Dual PARP/Tubulin Colchicine-Binding Site Inhibitors for Cancer Therapy

Zhouyan Liu, Tong Li, Yajing Chen, Dong Wei, Yueling Zhou, Cheng Chen, Yanyan Feng, Ziwei Tang, Zheying Zhu, Jinyi Xu, Jichao Chen

Journal of Medicinal Chemistry · 05.11.2026

DOI: 10.1021/acs.jmedchem.6c01966 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 05.11.2026. Verfasst von Zhouyan Liu und 10 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Nanjing University of Chinese Medicine, National Natural Science Foundation of China, Jiangsu Specially-Appointed Professors program.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual targeting of poly(ADP-ribose) polymerase (PARP) and the colchicine-binding site (CBS) of tubulin represents a promising strategy to overcome tumor heterogeneity and acquired resistance. Herein, a series of benzofused heterocyclic carboxamide derivatives were designed and synthesized as novel dual PARP/CBS inhibitors. Structure−activity relationship studies identified D13 as the most potent lead, demonstrating low-nanomolar antiproliferative activities (IC50 = 2−15 nM) across multiple cancer cell lines with high selectivity over normal cells. D13 inhibited PARP1/2 enzymatic activity and suppressed tubulin polymerization via CBS binding. D13 also induced G2/M arrest, DNA damage, and apoptosis, while blocking cell migration and tube formation. In an MDA-MB-231 xenograft model, D13 at 20 mg/kg achieved 72.3% tumor growth inhibition with dose-dependent efficacy and good tolerability, outperforming veliparib, phenstatin, and their combination. These findings validate dual PARP/CBS inhibition as a viable therapeutic strategy and support further development of D13 as an anticancer lead.

Förderung

  • Nanjing University of Chinese Medicine
  • National Natural Science Foundation of China
  • Jiangsu Specially-Appointed Professors program
  • Nanjing Science and Technology Innovation Project for Overseas Talents

Zitieren

APA

Liu, Z., Li, T., Chen, Y., Wei, D., Zhou, Y., Chen, C., Feng, Y., Tang, Z., Zhu, Z., Xu, J., & Chen, J. (2026). Identification and Optimization of Novel Dual PARP/Tubulin Colchicine-Binding Site Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01966

Vancouver

Liu Z, Li T, Chen Y, Wei D, Zhou Y, Chen C, et al. Identification and Optimization of Novel Dual PARP/Tubulin Colchicine-Binding Site Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01966

BibTeX
@article{Liu2026,
  author = {Liu, Zhouyan and Li, Tong and Chen, Yajing and Wei, Dong and Zhou, Yueling and Chen, Cheng and Feng, Yanyan and Tang, Ziwei and Zhu, Zheying and Xu, Jinyi and Chen, Jichao},
  title = {Identification and Optimization of Novel Dual PARP/Tubulin Colchicine-Binding Site Inhibitors for Cancer Therapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c01966}
}
Kostenlos starten →